LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lyell Immunopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.80+0.68 (+8.37%)
Close on Oct 19, 2026
- Market cap
- $205.60M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.70 (−46.67%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Lyell Immunopharma, Inc. saw revenue fall 55.0% to $27.00K over the twelve months to Jun 30, 2026. Free cash flow was -$133.97M.
Revenue
$27.00K
-55.0% vs. a year earlier
Operating income
-$256.50M
TTM Q2 2026
Free cash flow
-$133.97M
TTM Q2 2026
EPS, diluted
-$12.01
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $205.60M
- P/E ratio
- –
- Price to sales
- 7614.93
- Price to book
- 0.88
- Dividend yield
- –
- Free cash flow yield
- -65.16%
Fundamentals
- Revenue
- $27.00K
- Net income
- -$248.48M
- EPS, diluted
- -$12.01
- Free cash flow
- -$133.97M
- Book value per share
- $10.01
- Diluted shares
- 23M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$27.00K-55.0% YoY
Operating income
-$256.50M
Net income
-$248.48M
EPS, diluted
-$12.01
Free cash flow
-$133.97M
Reported periodTrailing twelve months